65,437 trials
Malaria
Primary: Percentage of Participants With Incidence of Transfusion-transmitted Malaria — 3.6; 21.6 Percentage of participants
Diabetes Mellitus, Type 2
Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 10.74 Percentage of Participants
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Metastatic Melanoma · Recurrent Melanoma · Stage III Cutaneous Melanoma AJCC v7
Primary: Progression-free Survival — 6.9; 2.3 months — p=0.002
Colonic Adenoma · Water Exchange Colonoscopy
Primary: Percentage of Overall Detected Adenomas Missed During the First Right-Colon Colonoscopy — 33.8; 17.5 percentage of detected adenomas
Crohn's Disease
Primary: Change in Bowel Wall Thickness (BWT) — 5; 4 mm
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Clofarabine — 15 mg/m^2 x 4 days (6-9)
Intracranial Arterial Stenosis · Intracranial Atherosclerosis · Ischemic Stroke
Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole — 732; 1756 nanogram per milliliter (ng/mL)
Nonalcoholic Steatohepatitis
Primary: Number of Participant With Hepatic Histological Improvement in NAS by ≥ 2 Points With at Least 1-Point Reduction in Either Lobular Inflammation or Hepatocellular…
Post-stroke Elbow Spasticity
Primary: Dynamic Component of Spasticity (Spasticity Angle) — 70; 60; 57.5 degree — p=<0.001
Sexual Violence · Primary Prevention
Primary: 3-Month Usability — 67.66 score on a scale
Low Back Pain
Primary: Change in Movement Data Over Time — 2.74; 1.1 Degrees
Psychology, Social · Adolescent Behavior
Primary: Trigger Pulls — 2.8; 0.01 Number of trigger pulls
Hearing Loss
Primary: in Situ Real-ear Aided Response (REAR) — -.21; -1.86; 0.05 dB